Efficacy of Janus kinase inhibitors in rheumatoid arthritis

Langbour, C.; Rene, Jessica; Goupille, Philippe; Alegria, Guillermo Carvajal

doi:10.1007/s00011-023-01717-z

Cited by 9 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding effectiveness overall, studies have shown JAKis to be non-inferior, or even superior, to tumour necrosis factor inhibitors (TNFis) both in clinical trials and in observational settings. [10][11][12][13][14] After recent evidence of differences in safety in distinct patient segments, it thus becomes relevant to also ask whether there are differences in the effectiveness of JAKis in the very same specific patient segments. However, to our knowledge, there has been no published assessment of relative effectiveness within defined patient subpopulations, here: specifically, in those patient groups where the safety concerns with JAKis may be the highest.…”

Section: Introductionmentioning

confidence: 99%

Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden

Bower,

Frisell,

di Giuseppe

et al. 2023

RMD Open

View full text Add to dashboard Cite

ObjectivesTo investigate whether the relative effectiveness of janus kinase inhibitors (JAKis) versus tumour necrosis factor inhibitors (TNFi) or other biological disease-modifying antirheumatic drugs in rheumatoid arthritis differ by the presence or absence of risk factors for cardiovascular (CV) disease, age, sex and smoking.MethodsThrough Swedish registers, we identified 13 493 individuals with 3166 JAKi, 5575 non-TNFi and 11 286 TNFi treatment initiations 2016–2022. All lines of therapy were included, with the majority in second line or higher. Treatment response was defined as the proportion reaching European Alliance of Associations for Rheumatology (EULAR) good response and Clinical Disease Activity Index (CDAI) remission, respectively, within 6 months. Crude percentage point differences in these proportions (JAKis, and non-TNFis, vs TNFis) overall and by risk factors were observed, and adjusted for confounders using linear regression models. Predicted probabilities of response and remission were estimated from adjusted Poisson models, and presented across CV risk and age.ResultsOverall, adjusted percentage point differences indicated higher response (+5.0%, 95% CI 2.2% to 7.9%) and remission (+5.8%, 95% CI 3.2% to 8.5%) with JAKis versus TNFis. The adjusted percentage point differences for response in those above 65, at elevated CV risk, and smokers were +5.9% (95% CI 2.7% to 9.0%), +8.3% (95% CI 5.3% to 11.4%) and +6.0% (95% CI 3.3% to 8.7%), respectively. The corresponding estimates for remission were +8.0% (95% CI 5.3% to 10.8%), +5.6% (95% CI 3.0% to 8.2%) and +7.6% (95% CI 5.5% to 9.7%).ConclusionsAs used in clinical practice, response and remission at 6 months with JAKis are higher than with TNFi. Among patients with risk factors of concern, effectiveness is similar or numerically further increased. For individualised benefit-to-risk ratios to guide treatment choice, safety and effectiveness in specific patient segments should be considered.

show abstract

Section: Introductionmentioning

confidence: 99%

Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden

Bower,

Frisell,

di Giuseppe

et al. 2023

RMD Open

View full text Add to dashboard Cite

show abstract

“…Current pharmacologic treatments for RA include glucocorticoids, traditional nonsteroidal anti-inflammatory drugs, and new biological agents [2]. Most RA patients can achieve clinical remission after treatment with the above drugs, while about 30% of RA patients still suffer from adverse effects of the current treatment [3]. Methotrexate, as the most commonly used anti-RA drug in clinical practice, has hepatotoxicity when taken for a long time.…”

Section: Introductionmentioning

confidence: 99%

Oxymatrine Alleviates Collagen-Induced Arthritis in Mice by Regulating the Immune Balance of T Cells

Cao

Mao

et al. 2023

Molecules

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic immunity and autoimmune disorders. We have previously found that oxymatrine (OMT), a natural alkaloid, can alleviate rheumatoid arthritis without knowing whether OMT can alleviate rheumatoid arthritis through gut microbiota. In this study, we found that OMT can alleviate collagen-induced arthritis in mice and reconstruct the immune balance of Th1/Th2, Treg/Th17, and Tfr/Tfh cells. Colon transcriptome gene enrichment analysis indicated that oxymatrine may alleviate collagen induced arthritis in mice through immune system process pathway. Furthermore, OMT significantly altered the gut microbiota variety, changed the composition of microbial colonies, and reshaped the gut microbiota of collagen-induced arthritis (CIA) mice, which may participate in the regulation of the balance of Th1/Th2, Treg/Th17, and Tfr/Tfh cells to alleviate collagen-induced arthritis in mice.

show abstract

Integrated phytochemistry and network pharmacology analysis to reveal effective substances and mechanisms of Bushen Quhan Zhiwang decoction in the treatment of rheumatoid arthritis

Zhang,

Yan,

et al. 2024

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Efficacy of Janus kinase inhibitors in rheumatoid arthritis

Cited by 9 publications

References 47 publications

Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden

Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden

Oxymatrine Alleviates Collagen-Induced Arthritis in Mice by Regulating the Immune Balance of T Cells

Integrated phytochemistry and network pharmacology analysis to reveal effective substances and mechanisms of Bushen Quhan Zhiwang decoction in the treatment of rheumatoid arthritis

Contact Info

Product

Resources

About